Abstract: The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient.

Abstract: The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient.

Abstract: A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist.

Abstract: Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal; and c) causing an improvement of the learning, memory capacities and/or motor function of the animal.

Abstract: A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg2+-containing compound; and a second pharmaceutical composition comprising a second effective amount of a COX-2 inhibitor.

Abstract: A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg2+-containing compound; and a second pharmaceutical composition comprising a second effective amount of a COX-2 inhibitor.

Abstract: Non-human animal models for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) are disclosed. The invention relates to a transgenic mouse whose genome comprises a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the brain of the mouse, in which the transgene comprises a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43). The transgenic mouse exhibits reduced or impaired learning and memory capacity, and may further exhibits progressively impaired or reduced motor functions. Methods of using such animal models are also disclosed.

Abstract: Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal; and c) causing an improvement of the learning, memory capacities and/or motor function of the animal.

Abstract: Non-human animal models for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) are disclosed. The invention relates to a transgenic mouse whose genome comprises a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the brain of the mouse, in which the transgene comprises a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43). The transgenic mouse exhibits reduced or impaired learning and memory capacity, and may further exhibits progressively impaired or reduced motor functions. Methods of using such animal models are also disclosed.

Abstract: A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist.

Abstract: Disclosed herein is a method for treating a progressive neurodegenerative disorder by systemically administering a composition containing an effective amount of a G-CSF receptor agonist. The composition can also be administered to inhibit the onset of a progressive neurodegenerative disorder in a subject at high risk thereof. A further method relates to selecting a G-CSF receptor agonist of high efficacy for treating a progressive neurodegenerative disorder.

Abstract: A method of determining whether a patient is deficient in spatial learning and memory. The method includes providing a sample from the patient, the sample containing an sgk gene product; and determining an sgk expression level in the sample. If the sgk expression level in the sample is lower than that in a sample from a normal person, it indicates that the patient is deficient in spatial learning and memory. Also disclosed are a method of identifying a compound for treating deficiency in spatial learning and memory and a method of treating such deficiency.

Abstract: A method of determining whether a patient is deficient in spatial learning and memory. The method includes providing a sample from the patient, the sample containing an sgk gene product; and determining an sgk expression level in the sample. If the sgk expression level in the sample is lower than that in a sample from a normal person, it indicates that the patient is deficient in spatial learning and memory. Also disclosed are a method of identifying a compound for treating deficiency in spatial learning and memory and a method of treating such deficiency.